الصفحة الرئيسية>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>Thalidomide-Piperazine-PEG1-NH2 diTFA

Thalidomide-Piperazine-PEG1-NH2 diTFA

رقم الكتالوجGC63221

ثاليدوميد-بيبرازين-PEG1-NH2 diTFA عبارة عن اتحاد مركب ليجند رابط مركب E3 يشتمل على يجند cereblon القائم على ثاليدومايد ورابط مستخدم في تقنية PROTAC

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide-Piperazine-PEG1-NH2 diTFA التركيب الكيميائي

الحجم السعر المخزون الكميّة
25 mg
504٫00
متوفر
50 mg
792٫00
متوفر
100 mg
1188٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Thalidomide-Piperazine-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1000.

مراجعات

Review for Thalidomide-Piperazine-PEG1-NH2 diTFA

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide-Piperazine-PEG1-NH2 diTFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.